Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05420948 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Suspended to Recruiting
    • Site details revised
    v8
  2. Trial status: Recruiting to Suspended Sponsor's reason: Paused to allow evaluation to determine if all enrolled subjects are evaluable
    • Site details revised
    v7
  3. Re-verified, no change to tracked fieldsv6
  4. Primary completion date: Dec 1, 2024 to Dec 1, 2026v5
  5. Re-verified, no change to tracked fieldsv4
Show 2 earlier versionsHide 2 earlier versions
  1. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Sep 1, 2023 to Oct 17, 2022
    v3
  2. Start date: Sep 1, 2022 to Sep 1, 2023
    • Study description revised
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
By doing this study, the research team would like to learn if using a blood test that measures the amount of tumor DNA in blood can help guide how to use chemotherapy combined with immunotherapy for individuals with head and neck cancer. Using this blood test, the research team hopes to learn if intermittent (occasional) chemotherapy added to immunotherapy will work better than immunotherapy alone. Participation in this research will last about two years.
Trial Details
NCT Number NCT05420948
Lead Sponsor University of Chicago
Conditions
(from sponsor)		 Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Neoplasms, Head Cancer, Throat Carcinoma
Related terms Head and Neck Neoplasms, Squamous Cell Carcinoma of Head and Neck
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov